PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsTirzepatide
Mounjaro (autoinjector), Mounjaro(tirzepatide)
Mounjaro, Zepbound (tirzepatide) is a protein pharmaceutical. Tirzepatide was first approved as Mounjaro (autoinjector) on 2022-05-13. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. It is known to target glucagon-like peptide 1 receptor and gastric inhibitory polypeptide receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
Mounjaro, Zepbound
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tirzepatide
Tradename
Company
Number
Date
Products
MOUNJARO (AUTOINJECTOR)Eli LillyN-215866 RX2022-05-13
6 products, RLD, RS
MOUNJAROEli LillyN-215866 RX2023-07-28
6 products, RLD, RS
ZEPBOUND (AUTOINJECTOR)Eli LillyN-217806 RX2023-11-08
6 products, RLD, RS
ZEPBOUNDEli LillyN-217806 RX2024-03-28
6 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
mounjaroNew Drug Application2025-01-14
zepboundNew Drug Application2025-03-12
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
type 2 diabetes mellitusEFO_0001360D003924E11
Agency Specific
FDA
EMA
Expiration
Code
TIRZEPATIDE, MOUNJARO, ELI LILLY AND CO
2027-05-13NCE
TIRZEPATIDE, MOUNJARO (AUTOINJECTOR), ELI LILLY AND CO
2027-05-13NCE
TIRZEPATIDE, ZEPBOUND, ELI LILLY AND CO
2027-05-13NCE
2026-11-08NP
Patent Expiration
Patent
Expires
Flag
FDA Information
Tirzepatide, Mounjaro, Eli Lilly And Co
113578202039-06-14DP
94747802036-01-05DS, DPU-3378
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BX: Other blood glucose lowering drugs, excl. insulins in atc
— A10BX16: Tirzepatide
HCPCS
No data
Clinical
No data
Drug
General
Drug common nameTirzepatide
INNtirzepatide
Description
Tirzepatide, sold under the brand name Mounjaro among others, is an antidiabetic medication used for the treatment of type 2 diabetes and for weight loss. Tirzepatide is administered via subcutaneous injections (under the skin).
Classification
Protein
Drug classpeptides
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID2023788-19-2
RxCUI—
ChEMBL IDCHEMBL4297839
ChEBI ID—
PubChem CID156588324
DrugBankDB15171
UNII IDOYN3CCI6QE (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
GLP1R
GLP1R
GIPR
GIPR
Organism
Homo sapiens
Gene name
GLP1R
Gene synonyms
NCBI Gene ID
2740
Protein name
glucagon-like peptide 1 receptor
Protein synonyms
GLP-1 receptor, GLP1 receptor, seven transmembrane helix receptor
Uniprot ID
Q99669
Mouse ortholog
Glp1r (14652)
glucagon-like peptide 1 receptor (Q1JQR8)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Mounjaro – Eli Lilly
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Zepbound – Eli Lilly
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
No data
Safety
Black-box Warning
Black-box warning for: Mounjaro, Zepbound
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use